Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: LOBEF )

0.0136 -0.0009 (-6.21%)
Streaming Delayed Price Updated: 11:18 AM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,832
Open 0.0136
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0145
Today's Range 0.0136 - 0.0136
52wk Range 0.0100 - 0.0284
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Lobe Sciences Provides Company Review of 2023
From Lobe Sciences Ltd.
Via Business Wire

Performance

YTD
-2.16%
-2.16%
1 Month
-5.56%
-5.56%
3 Month
-15.00%
-15.00%
6 Month
+15.25%
+15.25%
1 Year
-36.74%
-36.74%

More News

Read More
Lobe Sciences Provides Update on L-130 Clinical Program
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
From Lobe Sciences Ltd.
Via Business Wire
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
Via TheNewswire.com
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
From Lobe Sciences Ltd.
Via Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Via Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Via Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
From Lobe Sciences Ltd.
Via Business Wire
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
Via Benzinga
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
From Lobe Sciences Ltd.
Via Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
From Lobe Sciences Ltd.
Via Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
Via Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
Via Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
Via Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
Via FinancialNewsMedia
Exposures Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Trippy Trading: Top Psychedelic Stocks For 2023
Via TheNewswire.com
Topics Cannabis
Exposures Cannabis
Lobe Sciences Announces Incorporation of Australian Subsidiary
Via Newsfile
Lobe Sciences Announces Closing of Private Placement
Via Newsfile
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
Via Benzinga
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
Via Newsfile
Topics Cannabis
Exposures Cannabis
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.